Genmab A/S operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Genmab A/S with three other
miscellaneous service companies in Europe:
of UNITED KINGDOM
sales of £551.40 million [US$761.60 million]
of which 54%
was Operating Genus PIC),
(5.27 billion Swedish Kronor [US$611.39 million]
of which 61%
was LabTech), and
based in BELGIUM
(530.26 million Euros [US$629.02 million]
Sales were up sharply during the first
quarter of 2021 versus the previous year's first quarter.
During the first
quarter of 2021, sales at Genmab A/S totalled
1.58 billion Danish Kroner.
an increase of 77.2%
from the 892.00 million Danish Kroner in sales at the company during the first quarter of 2020.
Genmab A/S reported sales of 10.11 billion Danish Kroner (US$1.61 billion)
December of 2020.
increase of 88.4%
versus 2019, when the company's sales were 5.37 billion Danish Kroner.
Sales at Genmab A/S have increased during each of the previous five years
(and since 2015, sales have increased a total of 792%).